Serum albumin concentrations and oedema in the newborn
Sir, Cartlidge and Rutter have provided useful data relating serum albumin concentration to gestation and discuss its poor correlation with clinical oedema.' Their view, how- ever, that 'hypoalbuminaemia of prematurity' is a 'normal not a pathological finding' is debatable. A biochemical or clinical finding that is consistently associated with prematurity is not necessarily normal' and may indeed be undesirable. In this study the authors have examined only one clinical aspect of hypoalbuminaemia, oedema; yet low serum albumin concentration may have diverse effectsfor instance, on drug and bilirubin binding and toxicity.
Currently, we are analysing the relation between clinical outcome and plasma albumin concentration measured in over 4000 samples during a longitudinal study of 932 infants. Preliminary multiple regression analysis has reaffirmed the strong association between hypoalbuminaemia and respiratory disease, even after adjustment for gestation. Low plasma albumin concentration in this circumstance cannot be regarded as 'normal' and probably reflects excessive losses-for example, into alveoli-and the adverse effect of severe disease or suboptimal nutrition on protein synthesis by an immature liver. Yet sick infants must have comprised an appreciable proportion of the low gestation sample investigated by Cartlidge and Rutter.
These workers contend 'that measurement of serum albumin concentrations in preterm infants, either routinely or in the presence of oedema, is of little use in their management'. This conclusion might be misinterpreted. A low plasma albumin concentration may be used as a marker for the high risk neonate, may influence the interpretation of other biochemical findings, and may warrant intervention in its own right. Albumin estimation is cheap and, I believe, should not be abandoned as a routine investigation in very low birthweight infants in the neonatal period. Correspondence 215 methylprednisolone in doses of 30 mg/kg/day for three days, 20 mg/kg/day for four days, and subsequently 10, 5, and 2 mg/kg/day for one week each, respectively, followed by 1 mg/kg/day until their haemoglobin concentration reached 11 g/dl, as described previously in the treatment of childhood acquired aplastic anaemia.2 Haemoglobin reached this concentration in 34, 62, and 194 days, respectively.
Liver and spleen became normal in size, with rises in leucocyte and platelet counts and haemoglobin concentrations to normal, a decrease in reticulocyte count, and disappearance of normoblastaemia in the first two cases and improvement in the third child. The patients' plasma haemoglobin concentration and alkaline phosphatase activity decreased to normal, with normalisation of haptoglobin concentrations. Their bone marrow became normocellular as studied by needle aspiration, but their bones have not been influenced by treatment yet according to findings on x ray film.
Although currently one child could only detect light and still had mild exophthalmus and all had macrocrania, their growth and development were appropriate for their ages. The two younger cases still required 2-5 mg prednisone daily and the third was currently on intravenous treatment. With the exception of Cushingoid appearance during high dose administration, they did not have any side effects of treatment with corticosteroid, such as hypertension, hyperglycaemia, or growth retardation.
I would also like to question the laboratory findings of the authors' second case, who had a normal (or raised) haptoglobin concentration (5 mg/dl), despite pronounced plasma free haemoglobin (125 mg/dl), which 
